批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/02/23 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/02/23 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/08/10 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:ESOMEPRAZOLE SODIUM 剂型/给药途径:INJECTABLE;INTRAVENOUS 规格:EQ 40MG BASE/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021689 |
002 |
NDA |
NEXIUM IV |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Discontinued |
Yes |
No |
AP |
2005/03/31
|
ASTRAZENECA |
200882 |
002 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Discontinued |
No |
No |
AP |
2013/03/18
|
SUN PHARM |
205379 |
001 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Discontinued |
No |
No |
AP |
2015/09/25
|
ACCORD HLTHCARE |
204657 |
002 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Prescription |
No |
No |
AP |
2016/08/10
|
EUGIA PHARMA |
207181 |
001 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Prescription |
No |
No |
AP |
2017/03/06
|
DEVA HOLDING AS |
203349 |
002 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Prescription |
No |
No |
AP |
2020/04/01
|
GLAND PHARMA LTD |
215732 |
001 |
ANDA |
ESOMEPRAZOLE SODIUM |
ESOMEPRAZOLE SODIUM |
INJECTABLE;INTRAVENOUS |
EQ 40MG BASE/VIAL |
Prescription |
No |
Yes |
AP |
2022/02/10
|
SLATE RUN PHARMA |